{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:25:29Z","timestamp":1789500329536,"version":"build-2803163510"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Cryoglobulinemic vasculitis (CV) is an immune complex mediated small vessel vasculitis characterized by the presence of cryoglobulins in serum, often associated with hepatitis C infection, systemic autoimmune diseases or hematological conditions. The focus of this review is to provide an update on new insights into pathogenesis, epidemiology and therapies of infectious and noninfectious type II and type III CV.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>The introduction of new antiviral drugs for treatment of hepatitis C infection implied major changes in HCV-related CV, allowing to shed new lights on CV pathogenesis and mechanisms of relapse and, therefore, to increase the relevance of autoimmune diseases in CV epidemiology. Specific B-cell clones are involved in the production of pathogenic immune complexes that leads to small-vessel vasculitis. Therefore, both antiviral treatments [direct-acting antivirals (DAAs) and oral nucleot(s)ide analogues] and targeted anti-CD20 therapies (rituximab) prove to be safe and effective options, leading to a better prognosis. Association of Sj\u00f6gren syndrome and CV defines a specific phenotype of patients, characterized by severe manifestations and poor outcome.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Removing viral stimulation on B-cells through direct-acting antivirals and blocking B-cells proliferation and differentiation with rituximab are the goals of treatment of CV. However, further research is needed to identify prognostic factors of refractory and relapsing disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000989","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T10:00:19Z","timestamp":1698919219000},"page":"27-34","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":22,"title":["Cryoglobulinemic vasculitis: a 2023 update"],"prefix":"10.1097","volume":"36","author":[{"given":"Michele","family":"Moretti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Talarico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,11,1]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.37715","article-title":"2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides","volume":"65","author":"Jennette","year":"2013","journal-title":"Arthritis Rheum"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/0002-9343(74)90852-3","article-title":"Biologic and clinical significance of cryoglobulins. A report of 86 cases","volume":"57","author":"Brouet","year":"1974","journal-title":"Am J Med"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/ajh.26944","article-title":"Prognosis and long-term outcomes in type I cryoglobulinemia: a multicenter study of 168 patients","volume":"98","author":"Ghembaza","year":"2023","journal-title":"Am J Hematol"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/(SICI)1522-2683(19990301)20:3<606::AID-ELPS606>3.0.CO;2-N","article-title":"Two-dimensional electrophoretic analysis of cryoproteins: a report of 335 samples","volume":"20","author":"Tissot","year":"1999","journal-title":"Electrophoresis"},{"key":"R5-20250526","first-page":"218","article-title":"Impact of direct acting antivirals on hepatitis C virus-related cryoglobulinemic syndrome","volume":"67","author":"Zignego","year":"2021","journal-title":"Minerva Gastroenterol (Torino)"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1002\/ajh.23608","article-title":"Long-term outcome of monoclonal (type 1) cryoglobulinemia","volume":"89","author":"N\u00e9el","year":"2014","journal-title":"Am J Hematol"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/bjh.13196","article-title":"Clinico-biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases","volume":"168","author":"Harel","year":"2015","journal-title":"Br J Haematol"},{"key":"R8-20250526","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.jbspin.2019.01.016","article-title":"Cryoglobulinemia: an update in 2019","volume":"86","author":"Desbois","year":"2019","journal-title":"Joint Bone Spine"},{"key":"R9-20250526","first-page":"1231","article-title":"Peripheral neuropathy in mixed cryoglobulinaemia: clinical assessment and therapeutic approach","volume":"38","author":"Scarpato","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.3748\/wjg.v20.i24.7544","article-title":"Hepatitis C virus associated glomerulopathies","volume":"20","author":"Ozkok","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jhep.2021.09.023","article-title":"HCV-related lymphoproliferative disorders in the direct-acting antiviral era: from mixed cryoglobulinaemia to B-cell lymphoma","volume":"76","author":"Cacoub","year":"2022","journal-title":"J Hepatol"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/BOR.0000000000000757","article-title":"Cryoglobulinemic vasculitis: pathophysiological mechanisms and diagnosis","volume":"33","author":"Kolopp-Sarda","year":"2021","journal-title":"Curr Opin Rheumatol"},{"issue":"(Suppl 52)","key":"R13-20250526","first-page":"S115","article-title":"How HCV has changed the approach to mixed cryoglobulinemia","volume":"27","author":"Della Rossa","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/j.humimm.2013.08.273","article-title":"Hepatitis C virus (HCV) infection of peripheral blood mononuclear cells in patients with type II cryoglobulinemia","volume":"74","author":"Jab\u0142o\u0144ska","year":"2013","journal-title":"Hum Immunol"},{"issue":"(Suppl 129)","key":"R15-20250526","doi-asserted-by":"crossref","first-page":"171","DOI":"10.55563\/clinexprheumatol\/keip4u","article-title":"Cryoglobulins: putative effectors of adaptive immune response","volume":"39","author":"Basile","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.dld.2017.06.003","article-title":"IgG3 subclass: a possible trigger of mixed cryoglobulin cascade in hepatitis C virus chronic infection","volume":"49","author":"Basile","year":"2017","journal-title":"Dig Liver Dis"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1002\/art.30274","article-title":"Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fc\u03b3 receptors","volume":"63","author":"Gragnani","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2019.06.029","article-title":"TLR9 signalling in HCV-associated atypical memory B cells triggers Th1 and rheumatoid factor autoantibody responses","volume":"71","author":"Comarmond","year":"2019","journal-title":"J Hepatol"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2017-03-771238","article-title":"Reversion of anergy signatures in clonal CD21low B cells of mixed cryoglobulinemia after clearance of HCV viremia","volume":"130","author":"Del Padre","year":"2017","journal-title":"Blood"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.micpath.2015.12.007","article-title":"Peripheral lymphocyte subsets in chronic hepatitis C: effects of 12\u200aweeks of antiviral treatment with interferon-alpha plus ribavirin","volume":"91","author":"Oliveira","year":"2016","journal-title":"Microb Pathog"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"855513","DOI":"10.3389\/fimmu.2022.855513","article-title":"Proteomic profiling of cryoglobulinemia","volume":"13","author":"Liu","year":"2022","journal-title":"Front Immunol"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.3390\/v12121364","article-title":"The relevance of microRNAs in the pathogenesis and prognosis of HCV-disease: the emergent role of miR-17-92 in cryoglobulinemic vasculitis","volume":"12","author":"Lorini","year":"2020","journal-title":"Viruses"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/hon.3008","article-title":"B-cell activating factor (BAFF), BAFF promoter and BAFF receptor allelic variants in hepatitis C virus related cryoglobulinemic vasculitis and non-Hodgkin's lymphoma","volume":"40","author":"Grag2nani","year":"2022","journal-title":"Hematol Oncol"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/rheumatology\/kel174","article-title":"B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection","volume":"46","author":"Fabris","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"(Suppl 124)","key":"R25-20250526","first-page":"139","article-title":"Rheumatoid factor-producing CD21low anergic clonal B-cells in essential mixed cryoglobulinaemia: a model for autoantigen-driven pathogenesis of infectious and noninfectious cryoglobulinaemias","volume":"38","author":"Del Padre","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.dld.2020.12.124","article-title":"Selective decrease in complement C2 hemolytic activity is a sensitive marker for cryoglobulinemia and active disease in hepatitis C patients","volume":"53","author":"De Faria","year":"2021","journal-title":"Dig Liver Dis"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"14904","DOI":"10.1038\/s41598-022-18427-x","article-title":"Recognizing the new disorder \u2018idiopathic hypocryoglobulinaemia\u2019 in patients with previously unidentified clinical conditions","volume":"12","author":"Roccatello","year":"2022","journal-title":"Sci Rep"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"11602","DOI":"10.3390\/ijms241411602","article-title":"Serological and molecular characterization of hepatitis C virus-related cryoglobulinemic vasculitis in patients without cryoprecipitate","volume":"24","author":"Napodano","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"112687","DOI":"10.1016\/j.jim.2019.112687","article-title":"Sentinel biomarkers in HCV positive patients with mixed cryoglobulinemia","volume":"476","author":"Basile","year":"2020","journal-title":"J Immunol Methods"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"4418","DOI":"10.1093\/rheumatology\/keab157","article-title":"Solving the mystery of HBV-related mixed cryoglobulinemia: potential biomarkers of disease progression","volume":"60","author":"Pocino","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R31-20250526","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s13075-022-02857-z","article-title":"Cryoglobulinemia in systemic lupus erythematosus: a retrospective study of 213 patients","volume":"24","author":"Roubertou","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"103133","DOI":"10.1016\/j.autrev.2022.103133","article-title":"Clinical impact and prognosis of cryoglobulinemia and cryofibrinogenemia in systemic sclerosis","volume":"21","author":"De Almeida Chaves","year":"2022","journal-title":"Autoimmun Rev"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1093\/rheumatology\/keab939","article-title":"Clinical picture, outcome and predictive factors of lymphoma in primary Sj\u00f6gren's syndrome: results from a harmonized dataset (1981\u20132021)","volume":"61","author":"Chatzis","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.semarthrit.2020.07.013","article-title":"Cryoglobulinemic vasculitis in primary Sj\u00f6gren's syndrome: clinical presentation, association with lymphoma and comparison with hepatitis C-related disease","volume":"50","author":"Argyropoulou","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1002\/hep.28753","article-title":"Prospective study of guideline-tailored therapy with direct-acting antivirals for hepatitis C virus-associated mixed cryoglobulinemia","volume":"64","author":"Gragnani","year":"2016","journal-title":"Hepatology"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.cgh.2018.05.021","article-title":"Long-term efficacy of interferon-free antiviral treatment regimens in patients with hepatitis C virus-associated cryoglobulinemia vasculitis","volume":"17","author":"Cacoub","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.3390\/v13112249","article-title":"A review on extrahepatic manifestations of chronic hepatitis C virus infection and the impact of direct-acting antiviral therapy","volume":"13","author":"Mazzaro","year":"2021","journal-title":"Viruses"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/liv.14698","article-title":"Clinico-immunological outcomes of HCV-cured cryoglobulinemia: lower relapse rate with interferon-based than interferon-free therapy","volume":"41","author":"Colantuono","year":"2021","journal-title":"Liver Int"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.autrev.2019.06.008","article-title":"Recommendations for managing the manifestations of severe and life-threatening mixed cryoglobulinemia syndrome","volume":"18","author":"Galli","year":"2019","journal-title":"Autoimmun Rev"},{"key":"R40-20250526","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/hep.32281","article-title":"A prospective study of direct-acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort","volume":"76","author":"Kondili","year":"2022","journal-title":"Hepatology"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"e0268180","DOI":"10.1371\/journal.pone.0268180","article-title":"Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients","volume":"17","author":"Batsaikhan","year":"2022","journal-title":"PLoS One"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1002\/hep.21190","article-title":"Cryoglobulinemia is associated with steatosis and fibrosis in chronic hepatitis C","volume":"43","author":"Saadoun","year":"2006","journal-title":"Hepatology"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"823160","DOI":"10.3389\/fimmu.2022.823160","article-title":"Evolution of cryoglobulinemia in direct-acting antiviral-treated asian hepatitis C patients with sustained virological responses: a 4-year prospective cohort study","volume":"13","author":"Chang","year":"2022","journal-title":"Front Immunol"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/hep.31804","article-title":"Hematological and genetic markers in the rational approach to patients with HCV sustained virological response with or without persisting cryoglobulinemic vasculitis","volume":"74","author":"Gragnani","year":"2021","journal-title":"Hepatology"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"102923","DOI":"10.1016\/j.autrev.2021.102923","article-title":"Predictors of long-term cryoglobulinemic vasculitis outcomes after HCV eradication with direct-acting antivirals in the real-life","volume":"21","author":"Gragnani","year":"2022","journal-title":"Autoimmun Rev"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/liv.14053","article-title":"Long-lasting persistence of large B-cell clones in hepatitis C virus-cured patients with complete response of mixed cryoglobulinaemia vasculitis","volume":"39","author":"Visentini","year":"2019","journal-title":"Liver Int"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"1094871","DOI":"10.3389\/fimmu.2023.1094871","article-title":"Dual stimulation by autoantigen and CpG fosters the proliferation of exhausted rheumatoid factor-specific CD21low B cells in hepatitis C virus-cured mixed cryoglobulinemia","volume":"14","author":"Del Padre","year":"2023","journal-title":"Front Immunol"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/v13061032","article-title":"Hepatitis B virus-related cryoglobulinemic vasculitis: review of the literature and long-term follow-up analysis of 18 patients treated with nucleos(t)ide analogues from the Italian Study Group of Cryoglobulinemia (GISC)","volume":"13","author":"Mazzaro","year":"2021","journal-title":"Viruses"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10067-022-06391-w","article-title":"Management of mixed cryoglobulinemia with rituximab: evidence and consensus-based recommendations from the Italian Study Group of Cryoglobulinemia (GISC)","volume":"42","author":"Quartuccio","year":"2023","journal-title":"Clin Rheumatol"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"100194","DOI":"10.1016\/j.jtauto.2023.100194","article-title":"Preventive plasmapheresis for rituximab related flare in cryoglobulinemic vasculitis","volume":"6","author":"Fornero","year":"2023","journal-title":"J Transl Autoimmun"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"5996","DOI":"10.1182\/blood-2011-12-396028","article-title":"Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey","volume":"119","author":"Terrier","year":"2012","journal-title":"Blood"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.autrev.2013.11.006","article-title":"Predictors of early relapse in patients with noninfectious mixed cryoglobulinemia vasculitis: results from the French nationwide CryoVas survey","volume":"13","author":"Terrier","year":"2014","journal-title":"Autoimmun Rev"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/bab.1929","article-title":"Biomarkers of minimal residual disease in rituximab-treated patients with mixed cryoglobulinemia","volume":"68","author":"Basile","year":"2021","journal-title":"Biotechnol Appl Biochem"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"103034","DOI":"10.1016\/j.autrev.2022.103034","article-title":"Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature","volume":"21","author":"Pouchelon","year":"2022","journal-title":"Autoimmun Rev"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.transci.2010.03.001","article-title":"Plasma exchange for treating cryoglobulinemia: a descriptive analysis","volume":"42","author":"Rockx","year":"2010","journal-title":"Transfus Apher Sci"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.transci.2018.06.005","article-title":"Apheresis treatment of cryoglobulinemic vasculitis: a multicentre cohort study of 159 patients","volume":"57","author":"Marson","year":"2018","journal-title":"Transfus Apher Sci"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13075-022-02720-1","article-title":"Secular trends in cryoglobulinemia mortality in the USA in the era of direct-acting antivirals","volume":"24","author":"Guo","year":"2022","journal-title":"Arthritis Res Ther"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000989","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T21:20:37Z","timestamp":1748294437000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/BOR.0000000000000989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000989","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}